Connect with us

Cannabis

Cannabis Report 2019-2023 – Complete Guide for Investors

mm

Published

on

cannabis report

The cannabis market has a recent report of its progress in the US and there is a forecast released for the years 2019 to 2023 that will help newcomers in the market. The cannabis report provides extensive detail regarding the cannabis market in the United States of America that includes an intricate description of the market growth rate and size.

This report will be giving an analysis of the market in the United States of America regarding cannabis by depicting its values and segmentation. Moreover, the report has an in-depth analysis of all cannabis-derived products in the cannabis market through the product and the channel for product distribution.

Cannabidiol is the non-psychoactive component of cannabis that is available in both marijuana and hemp. These two are the types of the original plant.

The extraction of cannabidiol compounds is possible through giving heat or decarboxylating the CBD acid. The resultant product CBD does not induce and intoxication in the user and the user does not feel any high.

This compound found in the medical strains has many therapeutic benefits that help relieve chronic pain and is useful for a number of physical as well as psychological diseases.

Moreover, some studies suggest it to be helpful even for pets regarding anxiety and pain. That is the reason why many Americans are now bringing cannabis products home and making it a part of their daily routine.

In addition to these factors, the fact that cannabinoid also helps in the endocannabinoid system, it is rendered good for the immune system in humans.

It slows down the whole disease progressing state according to some studies. The strain is available in many different forms with varying THC and CBD content and their ratios if both are meant to be present in the same product.

The cannabidiol market has high hopes of becoming one of the most flourishing industries in the US market during these years.

Various growth-enhancing factors like aging population growth and cannabis culture getting promoted and advocated among millennials, increasing chronic pain diseases like arthritis and other diseases are some causes why cannabis is flourishing in the domestic as well as the international market.

Moreover, the removal of the hemp substance from the list of Controlled Substances Act has given it a legal edge due to which people are not avoiding the product from the fear of showing positive test results.

On the other side, the market is not yet marked safe from risks and challenges of any kind that hinder the progress of the crop. These issues include a vague legal framework and policy regarding cannabis cultivation and use and products that are not regulated.

The report regarding cannabis will be assessing the opportunities in the industry and outline the factors that would drive the growth of the industry. The growing cannabis market in the US in cultivating terms has also been forecasted in this report.

 

 

 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Cannabis And The Mental Health – The Risks Involved

Published

on

The cannabis plant consists of over 500 identified chemical constituents, out of which over 100 are cannabinoids. Cannabinoids interact with the endocannabinoid system – a naturally occurring communication network that exists in our brains and bodies. Varying amounts and combinations of the dosages of cannabis, can, in turn, affect several physiological and psychological processes in different ways such as – gastrointestinal function, appetite, pain, memory, movement, immunity, inflammation, and mental health are all included.

The complexity of cannabis, however, is what makes it a potential medication for numerous illnesses. The concern is the gap that exists between the hype about cannabis, and the research with evidence supporting the hype. The concern holds a lot of relevance to mental health, where the effectiveness of cannabis as a treatment for a variety of psychiatric conditions, such as depression, anxiety, post-traumatic stress, psychosis, and addiction, is touted.

However, the reality of cannabis is that it cannot be held on the extremes of being either strictly helpful or strictly harmful. Instead, discussion regarding the potential benefits and harms of cannabis are encouraged, but with careful and nuanced consideration of science, with an addition of a humble attitude.

The science regarding the role of the endocannabinoid system in mood regulation is very clear with respect to depression. The use of cannabis or particular cannabinoids, in the treatment of depressive disorders, has had no support from any randomized controlled trials yet. On the contrary, the existing scientific data is mixed and tilts towards the idea of the worsening and development of depressive symptoms, by the ingestion of cannabis plant material. Although these findings are not satisfying, they aren’t straightforward either.

Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two best-known examples of cannabinoids found in the cannabis plant. Generally, the production of anxiety and psychotic features has been shown by THC, especially at higher doses. Meanwhile, production of anxiolytic and antipsychotic effects have been shown by CBD

However, a person’s increased or decreased anxiety or psychotic symptoms after ingesting cannabis can be affected by several other variables. This could include

  • Potency levels – Any presence of other cannabis-related chemicals
  • The amount of cannabis used
  • The frequency of use by the patient
  • Any past experience with cannabis
  • The patient’s likelihood to develop and/or experience psychiatric symptoms

There is added confusion regarding the relationship between cannabis and addiction. According to scientific literature, a substantial minority of users could hold the possibility of cannabis addiction – euphoric effects of THC are expected to be held somewhat responsible for the addictive potential. This includes the possibility of cannabis addiction in one in ten people, which still holds the representation of a large number of people.

A replacement to opioids by cannabis is encouraged if the goal of the treatment would be the reduction of harm. However, cannabis treatment for other substance addictions is not the most ideal option. Addiction involves more complications than cannabis itself. That may be the reason that cannabis-based medicines cannot be the solution to the treatment of addiction, even while it may play a helpful role in it. Solutions of addiction may continue to be multipronged as the causes of it are multifaceted.

In conclusion, the person’s motive for cannabis use matters. Temporary relief and avoidance from uncomfortable thoughts and emotions may be provided by the use of cannabis but psychiatric and psychological treatments focus on the skills and coping mechanisms to confront the difficult thoughts and emotions. Research shows, use of cannabis with this motive could ultimately lead to difficulties with mental health symptoms, and addiction. Positive and negative reinforcement could be caused by mind-altering substances such as high THC cannabis products.

 

Continue Reading

Cannabis

Glaucoma and Cannabis : What Opthalmologists Have To Say

Published

on

Myths can stay around for a long time. One of them was about Cannabis being a potential treatment for glaucoma patients. Glaucoma is a complex eye condition that involves the damage of the optic nerve over time, initially reducing peripheral vision and ultimately leading to blindness. The higher than normal eye pressure (intraocular pressure or IOP) is one of the major causes of optic nerve damage.

With the legalization of medical and recreational cannabis use in more U.S. states and Canada, researchers have been studying the use of cannabis as possible treatments for various health conditions. Although research from the 1970s and 1980s has shown a detectable drop in intraocular pressure for three to four hours, after the consumption of cannabis – by smoking, or by the ingestion of TH in the form of pills or injection, treatment for glaucoma would require control of eye pressure for a complete 24 hours.

Studies show that ingestion of about 18 to 20 mg of THC, six to eight times daily, is required for the reduction and maintenance of intraocular pressure by 3 to 5 mm Hg. This could also include significant negative effects on mood, mental clarity, and lung health (if smoked). Driving, operation of machinery, or engagement in various common activities would be prohibited. Additionally, the amount of cannabis needed to be consumed every three to four hours makes it cost-prohibitive for a significant number of patients.

Comparatively, alcohol has moderate intraocular pressure-lowering effects for an hour after consumption. However, the consumption of alcohol would never be recommended by doctors as a treatment for glaucoma.

Is THC Effective or Reliable as a Treatment for Glaucoma?

THC eye drops, pills and cigarettes have been studied, and the results aren’t positive. Burning and irritated eyes were caused by eye drops, with no decrease in eye pressure. Similarly, no decrease in eye pressure was recorded, after the use of sublingual THC compounds either. Meanwhile, use of THC-containing pills and/or cigarettes was stopped by patients after 9 months, due to the side effects.

With further research about glaucoma, scientists have concluded that the high intraocular pressure in the fluid at the front of the eye, is not the sole cause of the optic nerve damage. Further evidence shows that another cause could be the reduced blood flow in the optic nerve. While cannabis may lower eye pressure, it also lowers the patient’s blood pressure. Thus, the potential of cannabis to lower blood pressure effectively cancels out its ability to lower intraocular pressure.

What About CBD?

Currently available cannabis and cannabis-derived compounds – like CBD is not a sufficient treatment for any eye condition, including glaucoma. Cannabis is not a practical treatment to maintain lowered eye pressure for 24 hours, in order to treat glaucoma.

CBD has gained a lot of attention and scrutiny in the last few years. Although CBD is a derivative of cannabis as well, it doesn’t cause any mood-altering effects. However, current research does not support the use of CBD as an effective treatment for glaucoma. On the contrary, a recent study has shown that an increase in IOP may be caused by the CBD, making glaucoma worse.

The Future of Cannabis For Glaucoma Treatment

Currently, ophthalmologists say that the only way to control glaucoma and control vision is to lower the patient’s intraocular pressure. Depending on the type of glaucoma and severity, ophthalmologists can use medications such as prescription eye drops or surgery, as a form of treatment for glaucoma.

Furthermore, cannabis or any other cannabis products are NOT RECOMMENDED for the treatment of glaucoma, by the American Academy of Opthalmology, along with the agreement of the American Glaucoma Society and the Canadian Opthalmological Society.

Continue Reading

Cannabis

Global Pandemic Gives Rise To Huge Sales Spikes For Cannabis

Published

on

Cannabis sales increase across US and Canada as lockdown continues. The population rushes to stockpile cannabis to prepare itself for the long period of self-isolation, due to the spread of the COVID-19 pandemic.

Between the time period of March 16 and March 22, key US markets, including California, Colorado, Oregon, and Alaska, experienced a 50 percent rise in sales of recreational cannabis, and a 41 percent rise in medical cannabis sales, from the same period last year, figures attained from cannabis point of sale and info system Flowhub exhibit.

With the death toll rising to 600 in both countries, several US states and Canadian provinces are issuing stay at home orders, limiting business operations, and closing down borders, in an attempt to actively work to combat the fast-spreading coronavirus.

Although many businesses have been shut down due to the orders of a lockdown, legalized cannabis dispensaries are allowed to continue their businesses despite the current crisis, and have been listed as “essential services” alongside hospitals and other health facilities, even in jurisdictions with the tightest lockdown protocols,

During the intensifying threat of the COVID-19 and increasing sales of cannabis across North America, Bank of America analyst Chris Carey commented that investors could be provided with a defensive move in a market downturn, by the cannabis sector. Carey further talked about the acceleration of cannabis purchases in North America, regardless of region.

Carey pointed out Aphria specifically, boosting its rating to a “buy”. According to the BNN Bloomberg, Carey had reportedly explained how the Ontario-based grower could be expected to see it’s market share in Canada increase.

Aphria and Tilray stocks rose during the same time period. Last week, Aphria’s shares had been reported to move from a low of US$1.97 (C$2.88) to hit US$2.72 (C$3.89), between the time period of March 18th to March 20th. Closing at US$2.51 (C$3.58) last week, they gained slightly more yesterday at US$2.54 (C$3.72) to end the day.

Meanwhile during March 19 to March 20, Tilry shares had risen twice as much, from a low US$2.56 to a high of US$5.03. Yesterday, the stock closed at US$3.85.

According to the OCS Director of Communications Daffyd Roderick, Canada’s most populated province, Ontario, the government-run Ontario Cannabis Store’s (OCS) website experienced escalating online sales in the last two weeks. Last weekend, orders were reported to be more than twice as high compared to two weeks ago.

On Sunday, Nova Scotia was reported to be the latest province to announce a COVID-19 emergency. The province’s liquor commission, that is responsible for the control of sales of cannabis in Nova Scotia, reported a spike of 76 percent in cannabis sales last week.

Sales were also booming in cannabis related beverage companies. One such case was reported by Jamie Pearson, CEO of California-based Bhang Inc, who makes and deals with cannabis-infused beverages, chocolates, and other products. Hence, Pearson is expecting boosted revenue and profits this quarter.

Pearson further claimed the most popular products to be edibles such as gummies, brownies, and chocolates, because of easier storage and accessibility even with precautions such as having gloves on.

Stuart Titus, CEO of California-based Medical Marijuana Inc informed Reuters that the reason behind the boost of Canadian sales was the fear of months of supply disruptions. However, caution is recommended by Titus and others, as they believe that the long-awaited reversal of fortune could potentially be nothing more than a short-lived relief.

Avis Bulbulyan, CEO of cannabis consulting firm Siva Enterprises, explained that even during a global crisis like the spread of the global pandemic, the cannabis industry seems to be recession-proof. Bulbulyan further added that the rise in customer demand is not expected to last very long during a time like this.

Continue Reading

Trending